Primary Care Voice

Can’t Control Blood Sugar on Multiple Meds? 24% May Not Be Type 2 Diabetes Hypercortisolism, LADA, Dawn vs Somogyi This episode explains that some people with persistently high blood sugar and A1C despite exercising, eating well, and taking two to three diabetes medications may have conditions that mimic type 2 diabetes, with an estimated 24% chance in difficult-to-control cases. It highlights hypercortisolism autonomous adrenal hormone production as a key cause, linking excess glucocorticoids to higher glucose and insulin resistance and mineralocorticoids to high blood pressure, and describes diagnosis with the overnight 1 mg dexamethasone suppression test checking dexamethasone level, cortisol greater 1.8, and ACTH and possible cure with treatment of adrenal adenoma/hyperplasia. It also reviews LADA diagnosed with C-peptide, dawn phenomenon vs Somogyi effect 2–3 AM glucose check, steroid/medication effects, lifestyle factors, and falsely elevated A1C from iron deficiency anemia or blood disorders.

CGRP Migraine Medication Revolution (2026): Prevention, Abortive Options & Avoiding Medication Overuse Dr. Kulmeet Kundlas explains that migraine is a neurological event affecting 1.2 billion people and often leads to pain, disability, and medication overuse headache when treated repeatedly with NSAIDs, triptans, or opioids. He describes migraine biology involving the trigeminal nerve and CGRP release causing blood vessel dilation, brain sensitization, and inflammation, along with four migraine stages and the lack of a definitive diagnostic test. Treatment should include prevention and abortive strategies, emphasizing CGRP-targeted therapies: monoclonal antibodies that neutralize CGRP for prevention (monthly, quarterly, or IV options, including use from age six and up) and oral CGRP receptor antagonists (gepants like Ubrelvy and Nurtec) for acute attacks, which are not shown to cause medication overuse headache. He recommends tracking attacks with a migraine diary, aims for a 50% reduction in frequency/severity/duration, notes evolving guidelines and insurance support for CGRP drugs as first-line therapy, and highlights preventing progression to chronic migraine, especially when attacks exceed four.

GLP-1 Medication Denials Explained: Wegovy, Zepbound, Ozempic & Mounjaro | Appeals, Medicare Bridge & Next Steps Dr. Kulmeet Kundlas explains why GLP-1 agonist prescriptions (Wegovy, Zepbound, Ozempic, Mounjaro) are frequently denied and how patients can navigate the process. He distinguishes denials based on whether the drug is prescribed for weight loss versus metabolic health conditions such as diabetes, sleep apnea, and fatty liver/NASH/MASH, noting that coverage rules differ. He discusses high cash prices ($1,000–$1,400), employer benefit exclusions, and how insurers verify approved indications. He outlines Medicare Bridge Program weight-loss eligibility tiers by BMI and comorbidities, advises patients to demand written denial reasons, and notes denials are often reversed with proper evidence and timely appeals. He also covers physician-to-physician appeals, Bridge Program resubmission requirements, and manufacturer direct-purchase programs with escalating costs as doses increase.

FDA Expands Mounjaro Approval for Heart Protection (Aug 28, 2026): What the SURPASE Trial Means for Type 2 Diabetes Dr. Kulmeet Kundlas explains the FDA’s August 28, 2026 approval change for Mounjaro (tirzepatide), stating it is now officially approved to reduce the risk of future heart attack and stroke in addition to lowering A1C, supporting weight loss, and improving related metabolic factors. He reviews the SURPASE trial, a large study across 30+ countries with about 13,000 patients, comparing Mounjaro to Trulicity and finding Mounjaro similarly protective and about 1% more effective (13% vs 12%) despite participants already maximizing blood pressure, cholesterol, lifestyle, and standard therapies. He discusses inflammation as a key mechanism via GLP-1 and GIP receptor activity, notes common GI side effects and contraindication with medullary thyroid carcinoma, and emphasizes benefits depend on continued diet, exercise, resistance training, and high-protein intake.

pre-diabetes explained by a primary care physician. Learn about common dietary mistakes that may hinder managing pre-diabetes effectively. 00:00 Important Update 01:27 Common Mistakes to Avoid 03:28 What the Evidence Shows 05:22 Red Flags to Watch For 06:54 Final Takeaway 07:18 What You Should Do Next 08:05 What Changed and Why This video discusses common dietary errors made by individuals with pre-diabetes, emphasizing the importance of balanced carbohydrate intake, the pitfalls of relying on sugar-free labels, and the role of lifestyle changes in managing blood sugar levels. Q: Why shouldn't I eliminate carbohydrates completely? A: Carbohydrates are essential for providing vitamins, minerals, protein, and fiber. Eliminating them entirely can be detrimental. Q: Are sugar-free products always a good choice? A: Not necessarily. Sugar-free labels can be misleading and do not always mean low in carbohydrates or nutritious. Q: Is honey or coconut sugar a healthier option? A: No, honey and coconut sugar can still cause blood sugar spikes and should be consumed in moderation. Q: Can supplements replace lifestyle changes? A: Supplements like cinnamon and vinegar may help, but they are not substitutes for lifestyle changes such as diet and exercise. Q: What is the plate method? A: The plate method involves filling half your plate with non-starchy vegetables, a quarter with protein, and a quarter with complex carbohydrates. Educational content by a board-certified primary care physician. Based on current clinical guidelines and peer-reviewed evidence. This content is for education only and does not replace medical care. Dr. Kulmeet Kundlas – Primary Care, FL Board-Certified Internist in Active Practice 25+ Years Caring for Adult Patients Focus: Diabetes, Heart, Thyroid, Obesity Education Only – Talk to Your Doctor Daily Preventive & Chronic Care Management

Prediabetes Diet: 7-Step Eating Plan to Lower Blood Sugar Without Cutting Carbs Dr. Kulmeet Kundlas explains that prediabetes doesn’t require eliminating carbohydrates or following one specific diet; sustainable, culturally acceptable patterns like Mediterranean, plant-based, or DASH can reduce progression to diabetes. He emphasizes that food quality, portion size, consistency, and overall lifestyle (exercise, sleep, stress, relationships, weight management) address insulin resistance, citing the Diabetes Prevention Program’s 58% risk reduction over about three years. Key targets include losing 5–7% body weight, exercising 150 minutes weekly plus resistance training, and using the plate method (half non-starchy vegetables, one quarter protein, one quarter carbohydrate). He advises avoiding sugary drinks, choosing whole fruit over juice, monitoring broader metabolic markers, and avoiding common mistakes like extreme carb restriction, assuming “natural” sugars are harmless, relying on supplements, or unsafe prolonged fasting. 00:00 Introduction 01:16 Is There a Best Prediabetes Diet? 03:22 Lifestyle Intervention & Weight Loss 06:39 How Food Affects Your Blood Sugar 10:29 The Plate Method 12:15 Monitoring Your Progress 13:34 Common Mistakes with Prediabetes 16:14 Your Prediabetes Action Plan 17:55 Conclusion & Sign-Off

type 2 diabetes treatment explained by a primary care physician. Dr. Kundlas discusses the evolution of type 2 diabetes treatment, highlighting the importance of individualized care and updated guidelines. 0:00 The Evolution of Diabetes Care 1:12 The Dangers of High Blood Sugar 2:08 Tailoring Treatment to the Individual 6:08 Revolutionizing Heart and Kidney Health 8:49 The Power of Continuous Glucose Monitoring Dr. Kundlas explains the shift in type 2 diabetes treatment towards a more individualized approach, emphasizing the importance of considering comorbidities and using medications that protect organs. The 2026 guidelines prioritize comprehensive care over simply lowering A1C levels. Q: Why is controlling blood sugar important? A: High blood sugar acts like a liquid razor blade, damaging blood vessels and leading to complications such as heart attacks and strokes. Q: What role does metformin play in current treatment? A: Metformin remains important but is not sufficient alone. It helps prevent the liver from producing excess glucose. Q: How have diabetes medications evolved? A: New medications not only control blood sugar but also protect the heart, kidneys, and other organs, reducing the risk of complications. Q: What should patients with heart or kidney disease consider? A: Patients with heart issues should consider GLP-1 agonists, while those with heart failure may benefit from SGLT2 inhibitors. Q: What lifestyle changes are recommended? A: Lifestyle changes such as diet, physical activity, and weight management remain foundational in diabetes management. Educational content by a board-certified primary care physician. Based on current clinical guidelines and peer-reviewed evidence. This content is for education only and does not replace medical care. Dr. Kulmeet Kundlas – Primary Care, FL Board-Certified Internist in Active Practice 25+ Years Caring for Adult Patients Focus: Diabetes, Heart, Thyroid, Obesity Education Only – Talk to Your Doctor

Why Seeing More Specialists Can Be Dangerous: The 3-Step Primary Care Prescription The script argues that modern healthcare is dangerously fragmented when patients rely on multiple specialists without a dedicated primary care doctor coordinating care, contributing to diagnostic errors that drive 32% of U.S. medical practice claims. It warns that this fragmentation is colliding with an aging “silver tsunami,” with adults over 65 projected to outnumber children by 2034, worsening chronic disease burden and costs (including $5.3 trillion annually). Citing research including Dr. Barbara Starfield and Stanford/Harvard data, it claims strong primary care access increases life expectancy by about 52 days and reduces heart attacks, strokes, cancer, disparities, duplication, and unnecessary testing, while organ-specific care adds far less. The video presents a three-step plan: secure a dedicated primary care “medical air traffic controller,” force continuity by avoiding uncoordinated urgent/ER care, and deploy preventive care using USPSTF Grade A/B recommendations, while emphasizing patient accountability for risk-factor changes.

FDA Approves First Oral PCSK9 Inhibitor: Lipfendra Explained (Who It’s For, Cost, Benefits, Myths) Dr. Kulmeet Kundlas discusses the FDA approval of the first oral PCSK9 inhibitor, Lipfendra, as a potential game changer for patients with high cholesterol who can’t reach LDL targets with current therapy. He explains how cholesterol and lipoproteins (LDL and HDL) work, why lowering LDL reduces heart attack, stroke, PAD, and death risk, and how statins and PCSK9-targeting therapy lower LDL through different mechanisms. Lipfendra is a 20 mg once-daily pill taken on an empty stomach, priced at about $310/month, and can lower LDL by roughly 56–59% with minimal side effects (e.g., diarrhea, dizziness). FDA-approved use is as add-on therapy for patients on statins not at goal, familial hypercholesterolemia, and established ASCVD; it is not a statin replacement. He addresses common myths, emphasizes lifestyle changes, and outlines likely insurance and prescribing steps. 00:00 The FDA Just Approved This — Why It Matters 01:00 From $1,400 Injection to a $310 Pill 02:04 How Cholesterol Actually Works in Your Body 03:46 Statins vs. PCSK9: Two Different Targets 04:23 Why Lowering LDL Saves Lives (The Numbers) 05:42 Why I'm Excited — and Why It's Add-On, Not Replacement 06:44 Who's a Candidate — the Three Approved Groups 08:41 How to Take It: 20mg, Empty Stomach, Wait 30 Minutes 08:59 The Molecular Redesign That Made a Pill Possible 09:32 How Much It Lowers LDL — Cost and Side Effects 10:04 5 Myths I Need to Clear Up 12:07 Your Next Steps: The 4 Hoops

Medicare GLP-1 Bridge: 7 Facts They Did not Tell You Overview Start date: July 1, 2026 End date: December 31, 2027 (18-month CMS Innovation Fund demonstration) Purpose: Expand access to anti-obesity GLP-1 medications for Medicare beneficiaries Processing: Outside Part D, centrally administered via Humana Copay: Flat $50/month per medication Covered Medications Semaglutide (Wegovy) Tirzepatide (Zepbound) Liraglutide (Saxenda)